FLEXISEQ
LIVE

Serial Number

79115213

Owner

Pro Bono Bio Entrepreneur Limited

Attorney

Roberta S. Bren

Filing Date

Dec 12, 2011

Add to watchlist:

No watchlists yet
View on USPTO

FLEXISEQ Trademark

Serial Number: 79115213 • Registration: 4437885

FLEXISEQ is a trademark filed by Pro Bono Bio Entrepreneur Limited on December 12, 2011. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Pro Bono Bio Entrepreneur Limited (10 trademarks)

4th floor,

Entity Type: 99

Trademark Details

Filing Date

December 12, 2011

Registration Date

November 26, 2013

Published for Opposition

September 10, 2013

Cancellation Date

March 6, 2026

Goods & Services

[ Medical devices in the nature of a carrier with nanostructures which cross through the skin for the treatment of pain and inflammation associated with osteoarthritis; ] molecular filtering devices for medical use, namely, a liquid or gel as a drug delivery device which filters through the skin and has a physical therapeutic effect at the point of complaint; medical [, veterinary ] and surgical devices, namely, a medical device which acts as a drug delivery system in the nature of non-pharmaceutical nanostructures that migrate through the skin and have a physical therapeutic effect at the point of complaint [ ; inhalers for medical purposes sold empty; injection devices, namely, medical syringes and medical fluid injectors; medical instruments and devices for the administration of pain relief therapy and prophylaxis preparations and substances ]

Pharmaceutical preparations and substances for the treatment of pain and inflammation; [ veterinary and sanitary preparations and substances for the treatment of pain and inflammation; chemical preparations for pharmaceutical purposes, namely, for the treatment of pain and inflammation; diagnostic preparations and substances for medical purposes for in vivo use; pharmaceuticals for treating osteoarthritis, oncology, cardiovascular disease, respiratory disease, inflammation, infection, gastrointestinal diseases and central nervous system diseases; diagnostic preparation for medical and veterinary use; topical and parenteral preparations of vesicles, namely, liquids or gels for the treatment of pain and inflammation; chemical preparations for the treatment of pain and inflammation in the form of vesicles for medical and veterinary purposes; pharmaceutical preparations being chemical membranes and chemical aggregates for medical and veterinary purposes; pharmaceutical preparations of arachidonic acids for the treatment of pain and inflammation; dispersions and dry preparations of liposomal active substance carriers for use as a pharmaceutical, cosmetic substance carrier, in the nature of a liquid, gel, cream, lotion or lipid; cosmeceutical preparations in the nature of medicated cosmetics; local anesthetics; steroids; anti-inflammatory drugs; pharmaceuticals for the treatment of nail fungal infections; vaccines; immunotherapeutic vaccines; topical and parenteral lipids for use in the treatment of pain and inflammation; ] medicated creams, medicated dispersions, medicated lotions, medicated ointments, medicated gels [, medicated solutions, medicated sprays, medicated lacquers and pharmaceutical solutions which form a film on the skin for the treatment of pain and inflammation; surfactants for medical use in the treatment of or prevention of cancer, infectious disease, fungal diseases, disease caused by parasites, eye disease, diseases of the central and peripheral nervous systems, cardiovascular disease, diseases affecting the immune system, inflammatory diseases, single gene disorders, diseases of the mouth, teeth, skin, hair and ear, bone and blood diseases and reproductive system disorders, the treatment of inflammation, asthma, atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrhoeic eczema, acne vulgaris, bronchospasm, atherothrombotic cardiovascular disorders, venous thrombotic disorders, pain, dysmenorrhea, hypercholesterolemia, hypertriglyceridemia, fatty acid metabolism, metal or other toxicity, Alzheimer's disease, gout, macular degeneration, age-related macular degeneration, fungal infection and disorders related to fatty acid deficiencies ]

[ Surfactants and lipids for use in the manufacture of personal care products, chemical products for in vitro and in vivo use in research and development ]

Filing History

CANCELLED SECTION 71
Mar 6, 2026 C71T
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Nov 26, 2022 REM4
INTERNATIONAL REGISTRATION RENEWED
Dec 30, 2021 RNWL
PARTIAL INVALIDATION PROCESSED BY THE IB
Nov 7, 2020 INNP
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Oct 1, 2020 INPS
INVALIDATION PROCESSED
Oct 1, 2020 INPC
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 8, 2020 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jan 8, 2020 NA75
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Jan 8, 2020 C75P
NEW REPRESENTATIVE AT IB RECEIVED
Jan 3, 2020 NREP
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 9, 2019 APRE
TEAS SECTION 71 & 15 RECEIVED
Nov 4, 2019 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Aug 9, 2019 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 26, 2018 REM3
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2016 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 13, 2014 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 27, 2014 FICS
FINAL DISPOSITION PROCESSED
Feb 27, 2014 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 26, 2014 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 26, 2013 R.PR
NOTIFICATION PROCESSED BY IB
Sep 15, 2013 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2013 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2013 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 28, 2013 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 28, 2013 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 7, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 7, 2013 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 15, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2013 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 15, 2013 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 11, 2013 GNFN
FINAL REFUSAL E-MAILED
Mar 11, 2013 GNFR
FINAL REFUSAL WRITTEN
Mar 11, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 14, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 14, 2013 CRFA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 8, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 8, 2013 REAP
ASSIGNED TO LIE
Feb 8, 2013 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 8, 2013 TROA
REFUSAL PROCESSED BY IB
Sep 1, 2012 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 15, 2012 RFCS
REFUSAL PROCESSED BY MPU
Aug 15, 2012 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 14, 2012 RFCR
APPLICATION FILING RECEIPT MAILED
Aug 14, 2012 MAFR
NON-FINAL ACTION WRITTEN
Aug 13, 2012 CNRT
ASSIGNED TO EXAMINER
Aug 8, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 8, 2012 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 2, 2012 REPR